Pas-004 Capsules

NF1 Mutation

Pasithea Therapeutics Corp.Phase 1Active

43/ 100

Provisional rating · Methodology v0.2

Rating breakdown

14 Active assets in the NF1 Mutation cohort.

Asset / Sponsor	Phase	Rating
gsk1120212 Novartis Pharmaceuticals	Phase 4	B
Dabrafenib Novartis Pharmaceuticals	Phase 4	B
Anti-Thymoglobulin, Rabbit Masonic Cancer Center, University of Minnesota	Phase 2	CCC
Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells Masonic Cancer Center, University of Minnesota	Phase 2	CCC
Fludarabine Masonic Cancer Center, University of Minnesota	Phase 2	CCC